MAPT (Ab-404) Antibody

Basic Research Questions

• What is MAPT (Ab-404) Antibody and what epitope does it recognize?

MAPT (Ab-404) Antibody specifically recognizes the tau protein when it is phosphorylated at serine 404 (pSer404). Tau (MAPT) is a microtubule-associated protein that promotes microtubule assembly and stability and is involved in the establishment and maintenance of neuronal polarity . The C-terminus of tau binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both . The antibody is available in both polyclonal and monoclonal formats, with the monoclonal version offering higher specificity for the phosphorylated epitope.

Commercially available antibodies targeting this epitope typically use a synthetic phosphopeptide derived from human isoforms Tau-4 around the phosphorylation site of Serine 404 as the immunogen . The sequence recognized typically contains the motif D-T-S(PO₃H₂)-P-R, where S(PO₃H₂) represents the phosphorylated serine residue .

• What applications can MAPT (Ab-404) Antibody be used for in tau research?

MAPT (Ab-404) Antibody can be used in multiple experimental applications:

When using this antibody, it's crucial to include proper controls, such as dephosphorylated samples or competition with the immunizing peptide, to ensure specificity of the signal detected .

• How does phosphorylation at Ser404 relate to tau pathology in neurodegenerative diseases?

Phosphorylation at Ser404 is a critical post-translational modification associated with pathological tau in several ways:

• Ser404 phosphorylation is prominent and stable in diseased tissue, making it an important target for therapeutic development

• The pSer404 epitope region can adopt an extended β-strand conformation that may be linked to the seeding core in tau oligomers

• Phosphorylation at Ser404 often occurs in conjunction with phosphorylation at Ser396, and the combined phosphorylation state of these two serines influences the conformation of this epitope region

• Increased phosphorylation at Ser396/Ser404 is observed in the presence of Aβ-amyloidosis, demonstrating a link between amyloid pathology and tau hyperphosphorylation

• The region containing pSer404 has received particular attention for therapeutic targeting because of its association with pathological tau conformations that contribute to aggregation

Importantly, the Ser396/Ser404 phosphorylation occurs early in disease progression and is considered a biomarker for early-stage tauopathy development.

• What sample preparation methods are recommended for optimal antibody performance?

For optimal detection of phosphorylated tau at Ser404, consider the following methodological approaches:

• Tissue Samples: Rapid post-mortem collection and snap-freezing are critical to prevent dephosphorylation by endogenous phosphatases. Use phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, and β-glycerophosphate) in all extraction buffers .

• Cell Lysate Preparation: For Western blotting, use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors. Typical protein concentration for detection should be 20-50 μg, though for low signal detection, up to 50 μg of protein and more concentrated primary antibody (1:500) may be used .

• Storage Conditions: Store antibody at -20°C for one year. For short-term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles as this may reduce antibody activity .

• Blocking Conditions: For Western blotting, blocking with 5% BSA in 1X TBST is recommended rather than milk, as milk contains phosphoproteins that can interfere with phospho-specific antibody binding .

Advanced Research Questions

• How specific is the MAPT (Ab-404) Antibody to phosphorylated Ser404 versus other phosphorylation sites?

The specificity of phospho-specific antibodies is a critical concern in tau research. Studies have demonstrated that commercially available antibodies can show a significant lack of specificity, and PTM-specific antibodies often recognize non-modified versions of the protein . For MAPT (Ab-404) antibodies:

• Cross-reactivity with other phosphorylation sites can occur, especially with those in proximity such as pSer396 and pSer400

• Detection may be hindered by other PTMs in close vicinity, complicating the interpretation of results

• Antibody specificity should be validated using peptide arrays and competition assays with phosphorylated and non-phosphorylated peptides

To ensure specificity, researchers should:

• Validate antibodies using phospho-peptide arrays

• Perform dephosphorylation controls with lambda phosphatase

• Test on samples from tau knockout models to confirm signal specificity

• Compare results across multiple anti-pSer404 antibodies from different sources

• How does the conformation of tau impact antibody binding at the Ser404 site?

Tau conformation significantly affects antibody recognition of the pSer404 epitope:

• The pSer404 epitope region can adopt an extended β-strand structure similar to the pathogenic tau epitope pSer422, which has been linked to the seeding core in tau oligomers

• X-ray crystallography studies of antigen-binding fragment (Fab)/epitope complex structures reveal that the pSer404 epitope conformation is affected by the phosphorylation state of neighboring residues, particularly Ser396

• Different antibodies targeting the same pSer404 epitope can have different binding modes: some antibodies (such as h4E6) have an antigen-binding pocket that accommodates the epitope from its C-terminal end, which differs from other anti-tau antibodies

• Tau proteins often undergo C-terminal truncation, and if residue 408 serves as a terminus in these truncated forms, it may affect antibody recognition of the pSer404 epitope in paired helical filaments (PHF) isolated from human tissues

These structural insights are important when designing immunotherapeutic approaches targeting the pSer404 epitope, as they can help develop antibodies that specifically recognize pathological tau conformations while minimizing binding to normal tau protein.

• What are the methodological considerations for using this antibody in different experimental models?

Different experimental models present unique challenges when using MAPT (Ab-404) antibodies:

Cell Culture Models:

• In human neuroblastoma (SH-SY5Y) cells treated with Aβ42 oligomers, altered nuclear tau levels and phosphorylation are observed, with changes in nucleolar tau distribution . When using the antibody in these models, nuclear extraction protocols must preserve phosphorylation status.

• For induced pluripotent stem cell (iPSC)-derived neurons, differentiation protocols significantly affect tau isoform expression and phosphorylation patterns. The antibody may detect different signal intensities depending on the maturation stage of neurons .

Animal Models:

• In transgenic mice expressing human tau (hTg-Tau model), MAPT (Ab-404) antibodies can detect phosphorylated tau, but the signal may vary depending on the mouse age and brain region .

• Humanized MAPT knock-in mice express all six tau isoforms present in humans and show higher tau phosphorylation at Ser-396/Ser-404 in the presence of Aβ-amyloidosis . These models provide a more accurate representation of human tau phosphorylation.

• Research indicates that pathological human tau interacts better with human tau than with murine tau, suggesting species-specific differences . This has implications for interpreting results from mouse models.

Human Tissue:

• Post-mortem interval significantly affects phosphorylation status; samples should be collected rapidly and frozen to preserve phosphorylation .

• Different brain regions show variable levels of tau phosphorylation; standardizing the anatomical regions examined is crucial for comparative studies.

• What are the latest approaches for using pSer404 antibodies in developing immunotherapies for tauopathies?

Immunotherapeutic approaches targeting phosphorylated tau at Ser404 represent a promising avenue for treating tauopathies:

• The Ser396/Ser404 region of tau is a key epitope region for antibody-mediated immune modulation in development of disease-modifying therapies for Alzheimer's disease . Crystal structures of anti-Ser404 monoclonal antibodies in complex with their epitopes have precisely mapped this epitope region and revealed its conformation.

• In animal models immunized against phosphorylated tau (including sites like pSer422), there is a decrease in aggregated tau and associated cognitive improvement, similar to immunotherapies targeting pSer396/pSer404 .

• Recent approaches include:

  • Antibody optimization: Engineering antibodies with increased specificity for pathological tau conformations while minimizing binding to normal tau

  • Epitope mapping: Using computational modeling and protein design to reveal key determinants of antibody-antigen binding and optimize small sets of protein variants to localize antibody epitopes

  • Multi-epitope targeting: Designing antibody panels that simultaneously target multiple phosphorylation sites including pSer404

  • Blood-brain barrier penetration: Developing antibody fragments or utilizing delivery systems to enhance CNS exposure

• A comprehensive approach involves validating antibody panels for detecting multiple post-translational modifications (PTMs) on tau using peptide arrays, immunoblotting, electrochemiluminescence ELISA, and immunofluorescence technologies .

• How does the signaling pathway leading to Ser404 phosphorylation interact with other tau modification pathways?

The signaling pathways leading to Ser404 phosphorylation involve complex interactions with other tau modification mechanisms:

• Kinases responsible for Ser404 phosphorylation: Multiple kinases phosphorylate this site, including GSK3β and CDK5 . GSK3β in particular plays a significant role in tauopathy, as it can phosphorylate numerous sites on tau including Ser404 .

• Cross-talk with Aβ pathology: Aβ42 oligomers induce subtle oxidative stress and nucleolar stress, leading to altered nuclear tau levels and phosphorylation, including at Ser404. This subsequently causes reduced ribosomal RNA synthesis and processing, reduced global level of newly synthesized RNA, and reduced protein synthesis .

• Relationship with other phosphorylation sites: The phosphorylation state of Ser396 and Ser404 is interconnected, with both sites often co-phosphorylated in pathological conditions. This dual phosphorylation influences the conformation of the epitope region .

• Impact on tau aggregation: Phosphorylation at Ser404, particularly when combined with phosphorylation at other sites, promotes the formation of tau oligomers with β-strand structure that may be linked to the seeding core in tau aggregates .

• Propagation mechanisms: Pathological tau species, including those phosphorylated at Ser404, can propagate from cell to cell in a prion-like fashion. Humanized tau models show accelerated propagation of pathological tau both in the absence and presence of Aβ-amyloidosis .

Understanding these complex interactions is crucial for developing targeted therapeutic approaches that address the underlying mechanisms of tau pathology.

• What methodological approaches can resolve contradictory experimental results when using pSer404 antibodies?

Researchers often encounter contradictory results when using phospho-specific antibodies. To resolve these discrepancies:

Antibody validation strategies:

• Use multiple antibodies from different sources that recognize the same epitope

• Validate antibody specificity using peptide competition assays

• Confirm specificity using phosphatase treatment controls

• Test on knockout samples to verify signal specificity

Experimental design considerations:

• Standardize tissue processing protocols to minimize variability in phosphorylation status

• Use consistent lysis buffers with appropriate phosphatase inhibitors

• Document post-mortem interval for human samples

• Account for age and gender effects on tau phosphorylation

Advanced analytical approaches:

• Complement antibody-based detection with mass spectrometry to quantify site-specific phosphorylation

• Use the TauPTM online tool for visualization of PTMs and their interactions on human tau

• Apply computational modeling to predict epitope accessibility in different tau conformations

• Consider using humanized tau models that better recapitulate human tau biology

Addressing methodological limitations:

• Document antibody lot-to-lot variability

• Report detailed methodological parameters (dilutions, incubation times, detection methods)

• Consider the impact of sample preparation on epitope accessibility

• Recognize that detection may be hindered by other PTMs in close vicinity to pSer404

By implementing these approaches, researchers can better resolve contradictory results and improve the reliability of findings related to tau phosphorylation at Ser404.